海港治疗公司
SPTX
17.83
+0.23
+1.31%
海港治疗公司
US · SPTX
#3277 按市值排名
上市于 2026
17.83
+0.23
+1.31%
实时 - 追踪5344个代码 - 心跳于83秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例上升了0.1个百分点。
机构持股
- 机构持股比例
- 102.15% +0.12pp
- 机构数量
- 62 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund41.28%
Public Company33.49%
Mutual Fund19.49%
Individual/Insider4.58%
Government Pension Fund3.69%
Hedge Fund3.53%
Sovereign Wealth Fund0.64%
主要股东 截至 2026-06-30
PureTech Health plc
31.17% · 16.69M 股
Arch Venture Partners, L.P.
11.76% · 6.29M 股
General Atlantic Service Company, L.P.
11.40% · 6.10M 股
Sofinnova Investments, Inc.
6.66% · 3.56M 股
Third Rock Ventures, LLC
3.85% · 2.06M 股
Canada Pension Plan Investment Board
3.69% · 1.98M 股
J.P. Morgan Asset Management, Inc.
3.33% · 1.79M 股
Foresite Capital Management, LLC
3.32% · 1.78M 股
T. Rowe Price Group, Inc.
2.44% · 1.31M 股
The Goldman Sachs Group, Inc.
2.23% · 1.19M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪40份申报 · 19次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| PureTech Health plc | -- | 31.17% |
| General Atlantic Service Company, L.P. | -- | 11.40% |
| Daphne Zohar | Chief Executive Officer | 2.23% |
| Steven Paul | Founder & Non-Employee Chair of the Board | 1.61% |
| Lana Gladstein | General Counsel | 0.06% |
| Antony Loebel | Chief Medical Officer & President of Clinical Development | 0.04% |
| Denice Torres | Independent Director | 0.03% |
| Robert Hombach | Independent Director | 0.02% |
| Lauren White | Chief Financial Officer | 0.01% |
| Michael Chen | Co-Founder & CSO | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-21 | Robert Hombach | Independent Director | Open Market Acquisition | +13,000 | $18.14 |
| 2026-05-03 | General Atlantic Service Company, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-05-03 | Steven Paul | Founder & Non-Employee Chair of the Board | Derivative Exercise and Retained | +67,031 | -- |
| 2026-05-03 | PureTech Health plc | -- | Derivative Exercise and Retained | +16,382,534 | -- |
| 2026-05-03 | Antony Loebel | Chief Medical Officer & President of Clinical Development | Derivative Exercise and Retained | +20,109 | -- |
| 2026-05-03 | Denice Torres | Independent Director | Derivative Exercise and Retained | +13,406 | -- |
| 2026-05-03 | Lana Gladstein | General Counsel | Derivative Exercise and Retained | +33,515 | -- |
| 2026-05-03 | Lauren White | Chief Financial Officer | Derivative Exercise and Retained | +6,702 | -- |
| 2026-05-03 | Michael Chen | Co-Founder & CSO | Derivative Exercise and Retained | +3,351 | -- |
| 2026-04-29 | Sandra Peterson | Independent Director | Other Derivative Acquisition | +12,258 | $18.00 |
| 2026-04-29 | Sandra Peterson | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Sharon Mates | Independent Director | Other Derivative Acquisition | +49,033 | $18.00 |
| 2026-04-29 | Steven Paul | Founder & Non-Employee Chair of the Board | Other Derivative Acquisition | +1,003,450 | $18.00 |
| 2026-04-29 | Steven Paul | Founder & Non-Employee Chair of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | PureTech Health plc | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Daphne Zohar | Chief Executive Officer | Other Derivative Acquisition | +1,758,599 | $18.00 |
| 2026-04-29 | Daphne Zohar | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Robert Hombach | Independent Director | Other Derivative Acquisition | +12,258 | $18.00 |
| 2026-04-29 | Robert Hombach | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | David Wheadon | Independent Director | Other Derivative Acquisition | +12,258 | $18.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
海港治疗公司 讨论区 0 条评论